Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Frequently asked questions
What sector does Novo Nordisk A/S Class B (0QIU) operate in?
Novo Nordisk A/S Class B belongs to the Other sector and operates in the Biotechnology industry.
What is Novo Nordisk A/S Class B (0QIU) current stock price?
As of the latest data, Novo Nordisk A/S Class B stock price is DKK 298.25, with a previous close of DKK 297.60. Novo Nordisk A/S Class B gained DKK 0.65 in the last trading session, representing a 0.22% increase.
What is Novo Nordisk A/S Class B (0QIU) current market capitalization?
Novo Nordisk A/S Class B market cap is approximately 1.01 trillion.
What is Novo Nordisk A/S Class B (0QIU) Earnings Per Share (EPS)?
The trailing EPS is DKK 14.86.
What is Novo Nordisk A/S Class B (0QIU) Price-to-Earnings (P/E) ratio?
Novo Nordisk A/S Class B current P/E ratio is 20.07.
Does Novo Nordisk A/S Class B (0QIU) pay dividends?
Yes. Novo Nordisk A/S Class B pays other dividends with an annualized yield of 3.92% and an estimated annual payout of DKK 11.70 per share.
When is Novo Nordisk A/S Class B (0QIU) next earnings report?
Novo Nordisk A/S Class B is expected to release its next earnings report on June 30, 2026.
What is Novo Nordisk A/S Class B (0QIU) beta (volatility) score?
Novo Nordisk A/S Class B has a beta of 0.210, indicating lower volatility than the overall market.
